HanchorBio

Immune-oncology company, using its Fc-Based Designer Biologics (FBDB™) platform to engineer ligand traps to synergistically block multi-ligand interactions required for adaptive and innate immune activation. Lead candidate HCB101 is a ligand trap that targets the SIPRα-CD47 signaling pathway and is currently in US Phase 1 clinical studies for advanced solid tumors and r/r NHL